Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients

Brain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress. Nevertheless, BDNF has not yet been investigated in psoriasis, a chronic inflammatory systemic disease that is exacerbated by stress. Therefore, our aim was to determine BDNF plasma levels in psoriasis patients and healthy controls. Adult patients (n = 94) presenting with psoriasis for at least 1 year were enrolled, and age-and gender-matched with healthy controls (n = 307) from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Participants had neither a previous history of coronary artery disease nor current episode of major depression. BDNF plasma levels were determined using the Promega ELISA kit. A general linear model was used to compare BDNF levels in psoriasis patients and controls, with age, gender, systolic blood pressure, serum fasting glucose, blood lipid levels, triglycerides, smoking status, and body mass index examined. After adjusting for clinical and demographic variables, significantly decreased BNDF plasma levels were observed in psoriasis patients (P = 0.01) (estimated marginal means of 3922 pg/mL; 95% CI = 2660-5135) compared with controls (5788 pg/mL; 95% CI = 5185-6442). Similar BDNF levels were found in both mild and severe cases of psoriasis. Our finding, that BDNF is decreased in psoriasis, supports the concept of a brain-skin connection in psoriasis. Further studies should determine if BDNF is increased after specific psoriasis treatments, and associated with different disease stages.

Palavras-chave

Brain derived neurotrophic factor, Psoriasis, Neurotrophins, Psychological stress, Case-control study

URI

https://observatorio.fm.usp.br/handle/OPI/11536

Referências

Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
Bath KG, 2013, NEUROSCIENCE, V239, P149, DOI 10.1016/j.neuroscience.2013.01.074
Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309
Brunoni AR, 2014, BRAZ J MED BIOL RES, V47, P1102, DOI 10.1590/1414-431X20143762
Consoli SM, 2006, DERMATOLOGY, V212, P128, DOI 10.1159/000090653
Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013
Fuchikami M, 2010, PSYCHIAT INVEST, V7, P251, DOI 10.4306/pi.2010.7.4.251
Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
Nunes M. A., 2011, REV HCPA, V31, P487
Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216
Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5
Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002
Quan C, 2014, MOL BIOL REP, V41, P7015, DOI 10.1007/s11033-014-3589-4
Raap U, 2006, ALLERGY, V61, P1416, DOI 10.1111/j.1398-9995.2006.01210.x
Rampton DS, 2011, J RHEUMATOL, V38, P43, DOI 10.3899/jrheum.110904
Saha RN, 2006, J NEUROIMMUNE PHARM, V1, P212, DOI 10.1007/s11481-006-9020-8
Saraceno R, 2006, BRIT J DERMATOL, V155, P876, DOI 10.1111/j.1365-2133.2006.07518.x
Staniak HL, 2014, ATHEROSCLEROSIS, V237, P847, DOI 10.1016/j.atherosclerosis.2014.11.004
Truzzi F, 2011, CELL DEATH DIFFER, V18, P948, DOI 10.1038/cdd.2010.162
Vasiadi M, 2012, BRIT J DERMATOL, V166, P1349, DOI 10.1111/j.1365-2133.2012.10843.x

Coleções

Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - LIM/51

Carregar mais

Página do item completo